Osteoarthritis and Bone Disorders News

Patients with hip or knee osteoarthritis should receive education and counsel on self-management strategies across repeat clinical visits, according to updated recommendations from EULAR.

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.

Men are at greater risk for multi-joint osteoarthritis in their lower extremities vs. women, while women and Black patients demonstrate more severe knee OA features, according to data published in The Journal of Rheumatology.

Among patients with Ehrlichia IgG, Rickettsia IgG or alpha-gal IgE following a tick bite, only those with heightened levels of alpha-gal IgE demonstrated musculoskeletal symptoms, specifically higher rates of knee pain, according to data.

The risk for all-cause mortality decreases among patients with knee or hip osteoarthritis who achieve slow-to-moderate, but not fast, weight loss via anti-obesity medications, according to data published in Arthritis & Rheumatology.

The FDA has added a boxed warning for denosumab to advise patients with advanced chronic kidney disease of an increased risk for severe hypocalcemia, according to an FDA drug safety communication.

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.

The FDA cleared a wearable vibration belt device as a non-pharmacologic treatment for postmenopausal women with osteopenia, according to an industry press release.

Machine learning algorithms can be effective in predicting osteoporosis among patients with rheumatoid arthritis, as well as identifying new predictive factors, according to data published in Nature Scientific Reports.

Patients with cirrhosis are less frequently screened for osteoporosis compared with the general population, and less than 25% with low bone density actually receive treatment, according to research in Alimentary Pharmacology & Therapeutics.